Connect with us

Hi, what are you looking for?


UniQure Shares Fall After Clinical Update From Huntington’s Disease Gene Therapy Trial

Skip to main content


UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington’s disease.

AMT-130 was generally well tolerated at the lower dose of 6×1012 vector genomes (vg).
There have been no serious adverse events (SAEs) related to AMT-130.
Related Link:DSMB Recommends UniQure To Continue Huntington’s Gene Therapy Trial Unchanged.
NfL increased as expected following the AMT-130 surgical procedure and returned to baseline. NfL remained relatively constant in the two untreated control patients.
Structural magnetic resonance imaging did not reveal any clinically meaningful safety findings at one year of follow-up.
Measurements of total and mutant HTT protein in the cerebral spinal fluid of the four patients were highly variable and inconclusive.
A clinical update on the low-dose cohort of ten patients, primarily focused on safety, is expected in Q2 of 2022.
Full safety and efficacy data from the first two cohorts are expected in 1H of 2023 after all patients in the higher-dose cohort have achieved one year of follow-up.
The U.S. Phase 1/2 trial of AMT-130 in a planned 26 patients with early manifest Huntington’s disease, split into a ten patient, low-dose cohort followed by a 16 patient, higher-dose cohort.
The multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up for five years.
UniQure also plans to initiate a third cohort in 2H of 2022 to explore alternative stereotactic navigation systems to simplify the placement of catheters for infusions of AMT-130.
Price Action: QURE shares are down 29.30% at $20.34 during the market session on the last check Thursday.

Related Articles (QURE)

Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet

31 Stocks Moving In Thursday’s Mid-Day Session

Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates

CSL Behring, UniQure’s Hemophilia B Gene Therapy Hits Primary Endpoint

A Look Into Healthcare Sector Value Stocks

Benzinga’s Top Ratings Upgrades, Downgrades For October 27, 2021

View the discussion thread.

Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Updated: Dec 6, 2021 Original: Dec 6, 2021 Author: Lyndon Abioye Tanya Sam from the Real Housewives of Atlanta is trending on Twitter today,...


This is an editorial about an article originally sourced by 2NEWS. In 2021, has seen some new trends in digital marketing that may...


HAZLETON — A lone worker loaded his belongings from an open garage at DBi Services’ corporate headquarters on North Conahan Drive Saturday morning. Original...


Stamford-based NBC Sports will broadcast English Premier League soccer games until 2028, after its parent company agreed on a six-year extension with the league....